<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52403">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423980</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-202</org_study_id>
    <nct_id>NCT02423980</nct_id>
  </id_info>
  <brief_title>G-Pen™ for Hypoglycemia Rescue in T1D</brief_title>
  <official_title>G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, exploratory pilot study in patients with T1D. The study will involve
      two daytime clinical research center visits 7-14 days apart. Subjects will receive a single
      injection of G-Pen™ (glucagon injection) at each visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with plasma glucose &gt; 70 mg/dl at 30 minutes post-treatment</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>For 90 minutes following treatment, plasma glucose with be measured every 5 minutes with an increase in plasma glucose to &gt;70 mg/dl within 30 minutes of treatment being considered a positive response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to plasma glucose &gt; 70 mg/dl</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>Following treatment, time in minutes required for plasma glucose to reach a concentration &gt;70 mg/dl will be determined for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hypoglycemia symptom scores from baseline to 30 minutes post-treatment will be assessed with a hypoglycemia symptom questionnaire.</measure>
    <time_frame>0-30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Glucagon 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg G-Pen™ (glucagon injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg G-Pen™ (glucagon injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <arm_group_label>Glucagon 1 mg</arm_group_label>
    <arm_group_label>Glucagon 0.5 mg</arm_group_label>
    <other_name>G-Pen™ (glucagon injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 24 months

        Exclusion Criteria:

          -  Pregnant or Lactating

          -  HbA1c &gt;10.5% at screening

          -  Use of &gt; 2.0 U/kg total insulin dose per day

          -  Inadequate bilateral venous access in both arms

          -  Renal insufficiency

          -  Congestive heart failure, NYHA class II, III or IV

          -  Active malignancy within 5 years from screening

          -  Major surgical operation within 30 days prior to screening

          -  Seizure or bleeding disorder

          -  Glycogen storage disease

          -  Active substance or alchohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 25, 2015</lastchanged_date>
  <firstreceived_date>April 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
